Loading...

Home
Stock
MIRA

MIRA Overview

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Stock Price Prediction Technical Valuation Financials Earnings Should I Buy News & Events

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

Loading chart...

High

0.990

Open

0.978

VWAP

0.96

Vol

30.02K

Mkt Cap

39.83M

Low

0.930

Amount

28.71K

EV/EBITDA(TTM)

--

Total Shares

42.02M

EV

30.72M

EV/OCF(TTM)

--

P/S(TTM)

--

MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.

Show More

Events Timeline

(ET)

2026-07-06

09:30:00

MIRA Pharmaceuticals Announces Preclinical Results for SKNY-1

2026-06-25 (ET)

2026-06-25

08:30:00

MIRA Pharmaceuticals Announces New Data on Mira-55

2026-06-17 (ET)

2026-06-17

08:30:00

Mira Pharmaceuticals Submits Ketamir-2 Clinical Trial Protocol to FDA

2026-06-04 (ET)

2026-06-04

08:30:00

MIRA Pharmaceuticals Signs Exclusive License Agreement with MIRALOGX

2026-05-27 (ET)

2026-05-27

08:20:00

MIRA Pharmaceuticals Expands Ketamir-2 License Agreement Worldwide

News

Newsfilter

06-17Newsfilter

MIRA Submits Phase 2a Trial Protocol for Ketamir-2

Clinical Trial Submission: MIRA Pharmaceuticals has submitted a Phase 2a clinical trial protocol to the FDA for Ketamir-2, aimed at evaluating its safety and efficacy in chemotherapy-induced peripheral neuropathy, addressing a significant gap in FDA-approved treatments.
Patient Need: Chemotherapy-induced peripheral neuropathy affects 30% to 40% of patients, with approximately 3 million new persistent cases estimated annually worldwide, highlighting the potential market demand and necessity for Ketamir-2 to improve patient quality of life.
Trial Design Advantage: The study employs a randomized, double-blind, crossover design where patients will receive either 300 mg or 600 mg of Ketamir-2 or a placebo, allowing for more reliable efficacy signals in a smaller sample size, with each participant's study duration lasting up to 82 days.
Safety Record: In the previously completed MIRA-001 Phase 1 study, no serious adverse events were reported among 56 healthy volunteers, supporting the safety profile and once-daily dosing schedule for Ketamir-2, laying a solid foundation for the upcoming Phase 2a trial.

Yahoo Finance

06-17Yahoo Finance

MIRA Submits Phase 2a Trial Protocol for Ketamir-2

Clinical Trial Submission: MIRA Pharmaceuticals has submitted a Phase 2a clinical trial protocol to the FDA for Ketamir-2, aimed at evaluating its safety and efficacy in chemotherapy-induced peripheral neuropathy (CIPN), addressing a significant gap in FDA-approved treatments.
Patient Recruitment Criteria: The trial will enroll patients who have experienced persistent CIPN for at least three months, requiring a baseline pain score of 4 or higher, ensuring the study's relevance and potential to provide new treatment options for millions of cancer survivors.
Study Design Advantages: Utilizing a randomized, double-blind, crossover design, patients will receive either 300 mg or 600 mg of Ketamir-2 or a placebo, allowing for a more reliable efficacy signal from a smaller sample size, enhancing the scientific rigor of the study.
Market Demand Context: CIPN affects 30% to 40% of chemotherapy patients, with no specific treatments available, and MIRA's Ketamir-2 is poised to meet this significant unmet medical need, potentially improving patients' quality of life.

Yahoo Finance

02-08Yahoo Finance

Cannabis Sector Update: Aurora's Strategic Shift Amid Record Medical Sales

Aurora Financial Performance: Aurora Cannabis reported net revenue of $94.2 million for Q3 2026, a 7% year-over-year increase, with global medical cannabis sales reaching $76.2 million, accounting for over 80% of total sales, indicating strong growth potential in the high-margin medical market.
Strategic Transformation Plan: Aurora announced plans to gradually exit select Canadian consumer cannabis markets to reduce sales and marketing costs, which is expected to significantly improve overall profit margins in the coming quarters.
Canopy Growth Results: Canopy Growth reported net revenue of $90.4 million for Q3 2026, with a nearly 50% reduction in net loss despite weak international performance, reflecting positive progress in cost control and market integration.
Cronos Brand Expansion: Cronos Group launched its premium Lord Jones brand in Israel, marking a significant step in its global expansion strategy aimed at meeting local market demands with high-quality products while enhancing brand recognition in international markets.

Benzinga

2025-07-03Benzinga

US Stocks Likely To Open Higher As Trump Announces Vietnam Trade Deal: S&P 500's Golden Cross 'Reason To Expect Better Than Average Returns,' Says Expert

U.S. Stock Market Update: U.S. stock futures rose slightly following President Trump's announcement of a trade deal with Vietnam, while the Nasdaq and NYSE will have early closures for Independence Day. The S&P 500 reached a record high, driven by gains in materials, technology, and energy sectors, despite a decline in private sector jobs reported by ADP.
Corporate Highlights: Notable stock movements included a 21% surge for Greenbrier Companies after strong earnings, while Franklin Covey dropped 7.82% due to disappointing results. Xponential Fitness saw an 18.63% increase after an SEC investigation concluded without action, and Global Interactive Technologies skyrocketed 223.31% amid significant corporate changes.

Benzinga

2025-07-03Benzinga

Why Datadog Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

Datadog's S&P 500 Inclusion: Datadog Inc's shares rose 10.6% in pre-market trading after the announcement of its inclusion in the S&P 500 index, effective July 9, 2025, replacing Juniper Networks.
Pre-Market Stock Movements: Several stocks experienced significant movements in pre-market trading, with Global Interactive Technologies surging 217.7% and Fly-E Group tumbling 25.8% following a reverse stock split announcement.

Benzinga

2025-07-03Benzinga

MIRA Pharmaceuticals' Marijuana Analog Mira-55 Shows Potent Pain Relief In Preclinical Study, Stock Jumps 50% After Hours

MIRA Pharmaceuticals Stock Surge: MIRA Pharmaceuticals' stock price jumped approximately 50.8% to $1.87 after the announcement of Mira-55, a synthetic marijuana analog that provides pain relief comparable to morphine without psychoactive effects.
Regulatory Advancements and Future Prospects: The DEA confirmed that Mira-55 is not a controlled substance, facilitating its clinical development, while the company also progresses with other pain management therapies and an acquisition aimed at enhancing its market position.

Valuation Metrics

The current forward P/E ratio for MIRA Pharmaceuticals Inc (MIRA.O) is 0.00, compared to its 5-year average forward P/E of -3.84. For a more detailed relative valuation and DCF analysis to assess MIRA Pharmaceuticals Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-3.84

Current PE

0.00

Overvalued PE

-0.24

Undervalued PE

-7.43

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-0.99

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.08

Undervalued EV/EBITDA

-2.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

best 3 cryptos to day trade

Intellectia · 24 candidates

Price Change Pct 24h: >= $0.00Turnover 24h: >= 0Volatility 24h: >= 0Is Trending: trueDollar Volume 24h: >= 0

Ticker

Name

Market Cap$

Stellar

7.20B

XRP

73.17B

Cardano

7.21B

Zcash

7.83B

LAB

4.44B

币安人生

770.92M

what crypto will go down for 2 days

Intellectia · 23 candidates

Price Change Pct 24h: <= $0.00Turnover 24h: >= 1,000,000Rsi Category: oversold, moderateMoving Average Relationship: PriceBelowMA5, PriceBelowMA20Macd: negative, bearish

Ticker

Name

Market Cap$

BNB

77.34B

Monero

5.97B

NEAR Protocol

2.77B

Ondo

1.71B

Toncoin

4.86K

siren

51.35M

cryptos bearish tomorrow

Intellectia · 57 candidates

Price Change Pct 24h: <= $0.00Rsi Category: oversold, moderateMoving Average Relationship: PriceBelowMA5, PriceBelowMA20Support Resistance Relationship: PriceFallBelowSupportMacd: negative, bearish

Ticker

Name

Market Cap$

Streamr

420.04K

MOBOX

1.55M

OneFootball Credits

4.01M

Suku

3.88M

Contentos

2.21M

Coq Inu

5.73M

rank these as best investment to worst

Intellectia · 269 candidates

Price Change Pct 24h: >= $0.00Turnover 24h: >= 0Rsi Category: moderateMoving Average Relationship: PriceAboveMA20, PriceAboveMA200

Ticker

Name

Market Cap$

Superp

1.40M

Depinsim

923.19K

DAR Open Network

11.12M

Rivalz Network

210.68K

Yei Finance

16.52M

Zeta

5.18M

best 12 hour crypto Prediction

Intellectia · 983 candidates

One Day Rise Prob: 0 - 100One Day Predict Return: -100.0% - 100.0%

Ticker

Name

Market Cap$

Bitcoin

1.50T

Ethereum

286.31B

Lombard

94.71M

World Liberty Financial USD

4.07B

Solana

49.16B

币安人生

0.00

Avi kon sa position but kru

Intellectia · 702 candidates

Moving Average Relationship: PriceAboveMA5, PriceAboveMA20, PriceAboveMA200, PriceCrossAboveMA20, PriceCrossDownMA20

Ticker

Name

Market Cap$

Bitcoin

1.47T

Ethereum

276.57B

BNB

83.02B

XRP

82.56B

Solana

48.94B

TRON

30.30B

stocks under $5 bullish tomorrow

Intellectia · 892 candidates

Price: <= $5.00One Day Rise Prob: >= 60

Ticker

Name

Market Cap$

UTStarcom Holdings Corp

23.27M

Tiziana Life Sciences Ltd

171.78M

MIRA Pharmaceuticals Inc

47.11M

Oriental Culture Holding Ltd

1.26M

Pineapple Financial Inc

17.95M

Cardiol Therapeutics Inc

111.11M

Intellectia · 924 candidates

Market Cap: >= 0

Ticker

Name

Market Cap$

Bitcoin

1.39T

Ethereum

256.51B

XRP

87.76B

BNB

87.36B

Solana

50.47B

TRON

29.17B

what Crypto has a higher volume right now

Intellectia · 1019 candidates

Ticker

Name

Market Cap$

Bitcoin

1.42T

Ethereum

251.64B

Solana

50.14B

NIGHT

840.27M

OFFICIAL TRUMP

939.99M

XRP

85.96B

what crypto is active today?

Intellectia · 1016 candidates

Ticker

Name

Market Cap$

Bitcoin

1.43T

Ethereum

251.33B

Solana

50.94B

World Liberty Financial USD

4.60B

XRP

86.23B

OPN

71.04M

Whales Holding MIRA

Trading Trends

Insider

Hedge Fund

Congress Trading

People Also Watch

Frequently Asked Questions

What is MIRA Pharmaceuticals Inc (MIRA) stock price today?

The current price of MIRA is 0.9478 USD — it has decreased -0.73

What is MIRA Pharmaceuticals Inc (MIRA)'s business?

MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.

What is the price predicton of MIRA Stock?

Wall Street analysts forecast MIRA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIRA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is MIRA Pharmaceuticals Inc (MIRA)'s revenue for the last quarter?

MIRA Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is MIRA Pharmaceuticals Inc (MIRA)'s earnings per share (EPS) for the last quarter?

MIRA Pharmaceuticals Inc. EPS for the last quarter amounts to -0.03 USD, decreased -72.73

How many employees does MIRA Pharmaceuticals Inc (MIRA). have?

MIRA Pharmaceuticals Inc (MIRA) has 3 emplpoyees as of July 08 2026.

What is MIRA Pharmaceuticals Inc (MIRA) market cap?

Today MIRA has the market capitalization of 39.83M USD.